Role of histone deacetylase inhibitors in diabetic cardiomyopathy in experimental models (Review)

Garmpi,Anna; Damaskos,Christos; Garmpis,Nikolaos; Kaminiotis,Vaios-Vasileios; Georgakopoulou,Vasiliki Epameinondas; Spandidos,Demetrios A.; Papalexis,Petros; Diamantis,Evangelos; Patsouras,Alexandros; Kyriakos,George; Tarantinos,Kyriakos; Syllaios,Athanasios; Marinos,Georgios; Kouraklis,Gregory; Dimitroulis,Dimitrios

doi:10.3892/mi.2022.51

Role of histone deacetylase inhibitors in diabetic cardiomyopathy in experimental models (Review)

Authors:
- Anna Garmpi
- Christos Damaskos
- Nikolaos Garmpis
- Vaios-Vasileios Kaminiotis
- Vasiliki Epameinondas Georgakopoulou
- Demetrios A. Spandidos
- Petros Papalexis
- Evangelos Diamantis
- Alexandros Patsouras
- George Kyriakos
- Kyriakos Tarantinos
- Athanasios Syllaios
- Georgios Marinos
- Gregory Kouraklis
- Dimitrios Dimitroulis
View Affiliations

Affiliations: First Department of Propedeutic Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece, Renal Transplantation Unit, Laiko General Hospital, 11527 Athens, Greece, N.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece, Cardiothoracic Department, Derriford Hospital, University Hospitals Plymouth, PL6 8DH Plymouth, United Kingdom, Department of Infectious Diseases‑COVID‑19 Unit, Laiko General Hospital, 11527 Athens, Greece, Laboratory of Clinical Virology, School of Medicine, University of Crete, 71003 Heraklion, Greece, Unit of Endocrinology, First Department of Internal Medicine, Laiko General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece, Endocrinology Unit, Academic Department of Internal Medicine, Agioi Anargyroi General Oncology Hospital, National and Kapodistrian University of Athens, 14564 Athens, Greece, Second Department of Pulmonology, Sotiria Hospital, 11527 Athens, Greece, Department of Endocrinology and Nutrition, General Hospital Santa Lucia, 30202 Cartagena, Spain, 1st Pulmonology Department Sismanogleio Hospital, 15126 Athens, Greece, First Department of Surgery, Laiko General Hospital, 11527 Athens, Greece, Department of Hygiene, Epidemiology and Medical Statistics, 11527 Athens, Greece, Department of Surgery, Evgenideio Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece, Second Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
Published online on: August 2, 2022 https://doi.org/10.3892/mi.2022.51
Article Number: 26
Copyright: © Garmpi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In diabetes, metabolic dysregulation, caused by hyperglycemia, leads to both structural and functional changes in cardiomyocytes and subsequently leads to the development of cardiomyopathy. Histone deacetylases (HDAC) are enzymes that regulate gene transcription. Their actions have been examined in the development of multiple disorders, such as cardiovascular diseases and diabetes. The use of HDAC inhibitors (HDACIs), as potential therapeutic agents against disease progression has yielded promising results. The present review article reports preclinical trials identified in which HDACIs were administered to mice suffering from diabetic cardiomyopathy (DCM), and discusses the role and mechanisms of action of HDAC and HDACIs in DCM. A review of the literature was performed using the PubMed database, aiming to identify publications in the English language concerning the role of HDACIs in DCM. More specifically, key words, separately and in various combinations, such as HDACIs, HDAC, diabetes, cardiomyopathy, heart failure and ischemia/reperfusion injury, were used. Furthermore, the references from all the articles were cross‑checked in order to include any other eligible studies. The full‑text articles assessed for eligibility were eight, covering the period from 2015 to 2019; finally, all of them were included. The use of HDACIs exhibited encouraging results against DCM progression through various mechanisms, including the reduction of reactive oxygen species generation, inflammatory cytokine production and fibrosis, and an increase in autophagy and angiogenesis.

View Figures

View References

1	Wang Y, Yang H, Huynh Q, Nolan M, Negishi K and Marwick TH: Diagnosis of nonischemic stage B heart failure in type 2 diabetes mellitus. JACC Cardiovasc Imaging. 11:1390–1400. 2018.PubMed/NCBI View Article : Google Scholar
2	Hölscher ME, Bode C and Bugger H: Diabetic cardiomyopathy: Does the type of diabetes matter? Int J Mol Sci. 17(2136)2016.PubMed/NCBI View Article : Google Scholar
3	Yilmaz S, Canpolat U, Aydogdu S and Abboud HE: Diabetic cardiomyopathy; Summary of 41 years. Korean Circ J. 45:266–272. 2015.PubMed/NCBI View Article : Google Scholar
4	Avogaro A, de Kreutzenberg SV, Negut C, Tiengo A and Scognamiglio R: Diabetic cardiomyopathy: A metabolic perspective. Am J Cardiol. 93:13A–16A. 2004.PubMed/NCBI View Article : Google Scholar
5	Jia G, Hill MA and Sowers JR: Diabetic cardiomyopathy: An update of mechanisms contributing to this clinical entity. Circ Res. 122:624–638. 2018.PubMed/NCBI View Article : Google Scholar
6	Dinarello CA: Anti-inflammatory agents: Present and future. Cell. 140:935–950. 2010.PubMed/NCBI View Article : Google Scholar
7	Zhang L, Du J, Yano N, Wang H, Zhao YT, Dubielecka PM, Zhuang S, Chin YE, Qin G and Zhao TC: Sodium butyrate protects-against high fat diet-induced cardiac dysfunction and metabolic disorders in type II diabetic mice. J Cell Biochem. 118:2395–2408. 2017.PubMed/NCBI View Article : Google Scholar
8	Jia G, Whaley-Connell A and Sowers JR: Diabetic cardiomyopathy: A hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia. 61:21–28. 2018.PubMed/NCBI View Article : Google Scholar
9	Dhingra R and Vasan RS: Diabetes and the risk of heart failure. Heart Fail Clin. 8:125–133. 2012.PubMed/NCBI View Article : Google Scholar
10	Rosano GM, Vitale C and Seferovic P: Heart failure in patients with diabetes mellitus. Card Fail Rev. 3:52–55. 2017.PubMed/NCBI View Article : Google Scholar
11	Marwick TH, Ritchi R, Shaw JE and Kaye D: Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy. J Am Coll Cardiol. 71:339–351. 2018.PubMed/NCBI View Article : Google Scholar
12	Serhiyenko VA and Serhiyenko AA: Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment. World J Diabetes. 9:1–24. 2018.PubMed/NCBI View Article : Google Scholar
13	Levelt E, Rodgers CT, Clarke WT, Mahmod M, Ariga R, Francis JM, Liu A, Wijesurendra RS, Dass S, Sabharwal N, et al: Cardiac energetics, oxygenation, and perfusion during increased workload in patients with type 2 diabetes mellitus. Eur Heart J. 37:3461–3469. 2016.PubMed/NCBI View Article : Google Scholar
14	Garmpi A, Garmpis N, Damaskos C, Valsami S, Spartalis E, Lavaris A, Patelis N, Margonis GA, Apostolou KG, Spartalis M, et al: Histone deacetylase inhibitors as a new anticancer option: How far can we go with expectations? J BUON. 23:846–861. 2018.PubMed/NCBI
15	Seto E and Yoshida M: Erasers of histone acetylation: The histone deacetylase enzymes. Cold Spring Harb Perspect Biol. 6(a018713)2014.PubMed/NCBI View Article : Google Scholar
16	Zwergel C, Stazi G, Valente S and Mai A: Histone deacetylase inhibitors: Updated studies in various epigenetic-related diseases. J Clin Epigenet. 2(1)2016.
17	Garmpis N, Damaskos C, Garmpi A, Nonni A, Georgakopoulou VE, Antoniou E, Schizas D, Sarantis P, Patsouras A, Syllaios A, et al: Histone deacetylases and their inhibitors in colorectal cancer therapy: Current evidence and future considerations. Curr Med Chem. 29:2979–2994. 2022.PubMed/NCBI View Article : Google Scholar
18	Garmpis N, Damaskos C, Garmpi A, Georgakopoulou VE, Sarantis P, Antoniou EA, Karamouzis MV, Nonni A, Schizas D, Diamantis E, et al: Histone deacetylase inhibitors in the treatment of hepatocellular carcinoma: Current evidence and future opportunities. J Pers Med. 11(223)2021.PubMed/NCBI View Article : Google Scholar
19	Damaskos C, Garmpis N, Karatzas T, Nikolidakis L, Kostakis ID, Garmpi A, Karamaroudis S, Boutsikos G, Damaskou Z, Kostakis A and Kouraklis G: Histone deacetylase (HDAC) inhibitors: Current evidence for therapeutic activities in pancreatic cancer. Anticancer Res. 35:3129–3135. 2015.PubMed/NCBI
20	Damaskos C, Garmpis N, Valsami S, Kontos M, Spartalis E, Kalampokas T, Kalampokas E, Athanasiou A, Moris D, Daskalopoulou A, et al: Histone deacetylase inhibitors: An attractive therapeutic strategy against breast cancer. Anticancer Res. 37:35–46. 2017.PubMed/NCBI View Article : Google Scholar
21	Garmpis N, Damaskos C, Garmpi A, Kalampokas E, Kalampokas T, Spartalis E, Daskalopoulou A, Valsami S, Kontos M, Nonni A, et al: Histone deacetylases as new therapeutic targets in triple-negative breast cancer: Progress and promises. Cancer Genomics Proteomics. 14:299–313. 2017.PubMed/NCBI View Article : Google Scholar
22	Damaskos C, Garmpis N, Valsami S, Spartalis E, Antoniou EA, Tomos P, Karamaroudis S, Zoumpou T, Pergialiotis V, Stergios K, et al: Histone deacetylase inhibitors: A novel therapeutic weapon against medullary thyroid cancer? Anticancer Res. 36:5019–5024. 2016.PubMed/NCBI View Article : Google Scholar
23	Spartalis E, Athanasiadis DI, Chrysikos D, Spartalis M, Boutzios G, Schizas D, Garmpis N, Damaskos C, Paschou SA, Ioannidis A, et al: Histone deacetylase inhibitors and anaplastic thyroid carcinoma. Anticancer Res. 39:1119–1127. 2019.PubMed/NCBI View Article : Google Scholar
24	Damaskos C, Tomos I, Garmpis N, Karakatsani A, Dimitroulis D, Garmpi A, Spartalis E, Kampolis CF, Tsagkari E, Loukeri AA, et al: Histone deacetylase inhibitors as a novel targeted therapy against non-small cell lung cancer: Where are we now and what should we expect? Anticancer Res. 38:37–43. 2018.PubMed/NCBI View Article : Google Scholar
25	Garmpis N, Damaskos C, Garmpi A, Spartalis E, Kalampokas E, Kalampokas T, Margonis GA, Schizas D, Andreatos N, Angelou A, et al: Targeting histone deacetylases in endometrial cancer: A paradigm-shifting therapeutic strategy? Eur Rev Med Pharmacol Sci. 22:950–960. 2018.PubMed/NCBI View Article : Google Scholar
26	Moschos MM, Dettoraki M, Androudi S, Kalogeropoulos D, Lavaris A, Garmpis N, Damaskos C, Garmpi A and Tsatsos M: The role of histone deacetylase inhibitors in uveal melanoma: Current evidence. Anticancer Res. 38:3817–3824. 2018.PubMed/NCBI View Article : Google Scholar
27	Garmpis N, Damaskos C, Garmpi A, Dimitroulis D, Spartalis E, Margonis GA, Schizas D, Deskou I, Doula C, Magkouti E, et al: Targeting histone deacetylases in malignant melanoma: A future therapeutic agent or just great expectations? Anticancer Res. 37:5355–5362. 2017.PubMed/NCBI View Article : Google Scholar
28	Gray SG: Epigenetic treatment of neurological disease. Epigenomics. 3:431–450. 2011.PubMed/NCBI View Article : Google Scholar
29	Savi M, Bocchi L, Sala R, Frati C, Lagrasta C, Madeddu D, Falco A, Pollino S, Bresciani L, Miragoli M, et al: Parenchymal and stromal cells contribute to pro-inflammatory myocardial environment at early stages of diabetes: Protective role of resveratrol. Nutrients. 8(729)2016.PubMed/NCBI View Article : Google Scholar
30	Bugger H and Abel ED: Molecular mechanisms of diabetic cardiomyopathy. Diabetologia. 57:660–671. 2014.PubMed/NCBI View Article : Google Scholar
31	Chen Y, Du J, Zhao YT, Zhang L, Lv G, Zhuang S, Qin G and Zhao TC: Histone deacetylase (HDAC) inhibition improves myocardial function and prevents cardiac remodeling in diabetic mice. Cardiovasc Diabetol. 14(99)2015.PubMed/NCBI View Article : Google Scholar
32	Lee TI, Kao YH, Tsai WC, Chung CC, Chen YC and Chen YJ: HDAC inhibition modulates cardiac PPARs and fatty acid metabolism in diabetic cardiomyopathy. PPAR Res. 2016(5938740)2016.PubMed/NCBI View Article : Google Scholar
33	Lee TI, Bai KJ, Chen YC, Lee TW, Chung CC, Tsai WC, Tsao SY and Kao YH: Histone deacetylase inhibition of cardiac autophagy in rats on a high-fat diet with low-dose streptozotocin-induced type 2 diabetes mellitus. Mol Med Rep. 17:594–601. 2018.PubMed/NCBI View Article : Google Scholar
34	Wu Y, Leng Y, Meng Q, Xue R, Zhao B, Zhan L and Xia Z: Suppression of excessive histone deacetylases activity in diabetic hearts attenuates myocardial ischemia/reperfusion injury via mitochondria apoptosis pathway. J Diabetes Res. 2017(8208065)2017.PubMed/NCBI View Article : Google Scholar
35	Ban K, Cooper AJ, Samuel S, Bhatti A, Patel M, Izumo S, Penninger JM, Backx PH, Oudit GY and Tsushima RG: Phosphatidylinositol 3-kinase gamma is a critical mediator of myocardial ischemic and adenosine-mediated preconditioning. Circ Res. 103:643–653. 2008.PubMed/NCBI View Article : Google Scholar
36	Leng Y, Wu Y, Lei S, Zhou B, Qiu Z, Wang K and Xia Z: Inhibition of HDAC6 activity alleviates myocardial ischemia/reperfusion injury in diabetic rats: Potential role of peroxiredoxin 1 acetylation and redox regulation. Oxid Med Cell Longev. 2018(9494052)2018.PubMed/NCBI View Article : Google Scholar
37	Xu Z, Tong Q, Zhang Z, Wang S, Zheng Y, Liu Q, Qian LB, Chen SY, Sun J and Cai L: Inhibition of HDAC3 prevents diabetic cardiomyopathy in OVE26 mice via epigenetic regulation of DUSP5-ERK1/2 pathway. Clin Sci (Lond). 131:1841–1857. 2017.PubMed/NCBI View Article : Google Scholar
38	Bocchi L, Motta BM, Savi M, Vilella R, Meraviglia V, Rizzi F, Galati S, Buschini A, Lazzaretti M, Pramstaller PP, et al: The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) restores cardiomyocyte contractility in a rat model of early diabetes. Int J Mol Sci. 20:1873–1885. 2019.PubMed/NCBI View Article : Google Scholar
39	Bagshi RA and Weeks KL: Histone deacetylases in cardiovascular and metabolic diseases. J Mol Cell Cardiol. 130:151–159. 2019.PubMed/NCBI View Article : Google Scholar
40	Larsen L, Tonnesen M, Ronn SG, Størling J, Jørgensen S, Mascagni P, Dinarello CA, Billestrup N and Mandrup-Poulsen T: Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells. Diabetologia. 50:779–789. 2007.PubMed/NCBI View Article : Google Scholar
41	Bogaard HJ, Mizuno S, Hussaini AA, Toldo S, Abbate A, Kraskauskas D, Kasper M, Natarajan R and Voelkel NF: Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats. Am J Respir Crit Cure Med. 183:1402–1410. 2011.PubMed/NCBI View Article : Google Scholar
42	Hur KY, Jung HS and Lee MS: Role of autophagy in β-cell function and mass. Diabetes Obes Metab. 2 (12 Suppl):S20–S26. 2010.PubMed/NCBI View Article : Google Scholar
43	Weems J and Olson AL: Class II histone deacetylases limit GLUT4 gene expression during adipocyte differentiation. J Biol Chem. 286:460–468. 2011.PubMed/NCBI View Article : Google Scholar
44	Thai MV, Guruswamy S, Cao KT, Pessin JE and Olson AL: Myocyte enhancer factor 2 (MEF2)-binding site is required for GLUT4 gene expression in transgenic mice. Regulation of MEF2 DNA binding activity in insulin-deficient diabetes. J Biol Chem. 273:14285–14292. 1998.PubMed/NCBI View Article : Google Scholar
45	Shao D and Tian R: Glucose transporters in cardiac metabolism and hypertrophy. Compr Physiol. 6:331–351. 2015.PubMed/NCBI View Article : Google Scholar
46	Kao YH, Liou JP, Chung CC, Lien GS, Kuo CC, Chen SA and Chen YJ: Histone deacetylase inhibition improved cardiac functions with direct antifibrotic activity in heart failure. Int J Cardiol. 168:4178–4183. 2013.PubMed/NCBI View Article : Google Scholar